Literature DB >> 8186287

In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy.

W L Bi1, L M Parysek, R Warnick, P J Stambrook.   

Abstract

Tumor cells transduced with a retroviral vector expressing a herpes virus thymidine kinase (HSV tk) gene are rendered sensitive to the antiherpetic drug, ganciclovir. The bystander effect refers to the observation that not all cells need be transduced to eradicate the cell population by treatment with ganciclovir. We demonstrate that metabolic cooperation can account for this bystander effect. When HT1080 human fibrosarcoma cells marked with a lacZ gene (LZ+5) were cocultured with HT1080 cells transduced with a retrovirus expressing HSVtk (HT1080tk11), at a density at which the majority of cells were in contact, both HT1080tk11 and LZ+5 cells were killed by ganciclovir. When cells were cocultured at a low density where the majority of cells are not in contact with one another, however, only the HT1080tk11 cells were killed. This result suggests that cell contact with HT1080tk11 cells is necessary to render the HSVtk- LZ+5 cells sensitive to ganciclovir. Because involvement of metabolic cooperation in the killing of the LZ+5 cells would require not only contact between HT1080tk11 and LZ+5 cells but also the capacity to transfer small cytotoxic molecules from the former cell to the latter, transfer of radioactive molecules between the two cell lines was assessed by autoradiography after treatment of a coculture with [3H]ganciclovir. Isolated HT1080tk11 cells incorporated the labeled ganciclovir into their nuclei, whereas isolated LZ+5 cells did not. LZ+5 cells incorporated [3H]ganciclovir, only when in contact with HT1080tk11 cells. These findings indicate that a ganciclovir metabolic product, presumably a phosphorylated form, can pass from HSV tk+ to HSV tk- cells and mediate cytotoxicity as a consequence of direct contact.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8186287     DOI: 10.1089/hum.1993.4.6-725

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  53 in total

Review 1.  Gene therapy for liver diseases: recent strategies for treatment of viral hepatitis and liver malignancies.

Authors:  V Schmitz; C Qian; J Ruiz; B Sangro; I Melero; G Mazzolini; I Narvaiza; J Prieto
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

2.  Cytokine regulation of gap junction connectivity: an open-and-shut case or changing partners at the Nexus?

Authors:  C F Brosnan; E Scemes; D C Spray
Journal:  Am J Pathol       Date:  2001-05       Impact factor: 4.307

3.  Regulation of cellular proliferation and intimal formation following balloon injury in atherosclerotic rabbit arteries.

Authors:  R D Simari; H San; M Rekhter; T Ohno; D Gordon; G J Nabel; E G Nabel
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

Review 4.  Anti-tumor gene therapy.

Authors:  C Cirielli; M C Capogrossi; A Passaniti
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

5.  Combination gene delivery of the cell cycle inhibitor p27 with thymidine kinase enhances prodrug cytotoxicity.

Authors:  X Danthinne; K Aoki; A L Kurachi; G J Nabel; E G Nabel
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

6.  Plasmoviruses: nonviral/viral vectors for gene therapy.

Authors:  P Noguiez-Hellin; M R Meur; J L Salzmann; D Klatzmann
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

Review 7.  Development of retroviral vectors as safe, targeted gene delivery systems.

Authors:  W H Günzburg; B Salmons
Journal:  J Mol Med (Berl)       Date:  1996-04       Impact factor: 4.599

Review 8.  Clinical trials with retrovirus mediated gene therapy--what have we learned?

Authors:  Nikolai G Rainov; Huan Ren
Journal:  J Neurooncol       Date:  2003-12       Impact factor: 4.130

9.  The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro.

Authors:  J Fick; F G Barker; P Dazin; E M Westphale; E C Beyer; M A Israel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

Review 10.  Gene therapy for PNET.

Authors:  C Raffel
Journal:  J Neurooncol       Date:  1996-07       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.